Introduction {#s1}
============

Lysosomes are the cell's recycling center equipped with the most important nutrient-sensing machinery in the cell ([@bib21]; [@bib24]). Ion channels in the lysosome play essential roles in the regulation of various lysosomal functions, including cargo import, lysosomal degradation, and catabolite export ([@bib24]; [@bib47]). Patch-clamp studies of isolated lysosomal membranes have recently discovered multiple lysosomal channels that are selective for Na^+^, K^+^, Ca^2+^, and Cl^-^ ([@bib8]; [@bib6]; [@bib9]; [@bib13]; [@bib24]; [@bib45]; [@bib47]). How these lysosomal channels are activated by endogenous nutrient-dependent signals remain largely unknown ([@bib24]). On the other hand, membrane-permeable small-molecule modulators, that is synthetic agonists and inhibitors, have proved extremely helpful in probing the cell biological functions of intracellular channels, including lysosomal channels ([@bib9]; [@bib13]; [@bib24]; [@bib45]; [@bib47]). For example, small-molecule synthetic agonists of Mucolipin TRP channels (TRPMLs), that is ML-SAs, have been instrumental in revealing the functions of these Ca^2+^ release channels in lysosomal exocytosis, mobility, and biogenesis ([@bib23]; [@bib42]; [@bib50]). However, such chemical tools are still lacking for most other lysosomal channels.

Two-pore channel proteins (TPC1, 2; *TPCN1, TPCN2*) are ubiquitously expressed, dimeric, two-repeat (2 × 6 TM) cation channels that are localized exclusively in the intracellular endosomes and lysosomes ([@bib5]; [@bib14]; [@bib29]). At the cellular level, TPCs regulate organellar membrane excitability, membrane trafficking, and pH homeostasis; at the organismal level, TPCs regulate various physiological and pathological processes, including hair pigmentation, *Ebola* viral infection, and cancer growth ([@bib1]; [@bib32]; [@bib37]). Early works from several laboratories suggested that TPCs play an essential role in mediating Ca^2+^ release from endolysosomes in response to cytosolic increases of nicotinic acid adenine dinucleotide phosphate (NAADP) ([@bib4]; [@bib5]; [@bib35]; [@bib51]). However, it remains controversial whether TPCs are the *bona fide* NAADP receptor ([@bib25]; [@bib30]; [@bib44]). Indeed, several recent endolysosomal patch-clamp studies have demonstrated that TPCs are Na^+^-selective channels activated by PI(3,5)P~2~ ([@bib3]; [@bib7]; [@bib6]; [@bib16]; [@bib19]; [@bib20]; [@bib41]; [@bib45]), a late endosome and lysosome-specific phosphoinositide that is known to regulate many aspects of lysosome function ([@bib28]). Recent high-resolution structural studies revealed that several amino acid (AA) residues in the selectivity filter of TPCs confer the selectivity of Na^+^ over K^+^ or Ca^2+^ ([@bib15]; [@bib16]), and that PI(3,5)P~2~ binds directly to several positively charged AA residues in the S4-S5 linker to induce channel opening ([@bib20]; [@bib40]; [@bib41]). Sphingosines also reportedly induce TPC1-mediated Ca^2+^ release from the lysosomes ([@bib17]), but direct activation of TPCs by sphingosines was not confirmed in the lysosomal electrophysiological assays (unpublished data in the Xu laboratory) ([@bib24]).

Lysosomal membrane potential (Δψ) has been proposed to regulate an array of lysosomal functions, including metabolite transport and membrane trafficking, but the underlying mechanisms are poorly understood ([@bib24]; [@bib48]). Na^+^ flux mediated by TPCs may cause rapid changes of lysosomal Δψ , which may in turn modulate the functions of TPCs and other lysosomal channels ([@bib7]). Like canonical voltage-gated cation channels, TPCs contain multiple positively-charged AA residues in their voltage sensor domains (S4), which are believed to confer voltage-dependent activation of plant and animal TPC1 channels ([@bib7]; [@bib41]). In a sharp contrast, TPC2 activation is completely voltage-independent, despite the presence of multiple Arginine/Lysine residues in their S4 helices ([@bib7]; [@bib6]; [@bib45]). In the current study, we identified seven small molecules known to act as tri-cyclic anti-depressants (TCAs) that activate both TPC1 and TPC2 in a voltage-dependent manner.

Results {#s2}
=======

High-throughput screening of small-molecule agonists of TPC2 channels {#s2-1}
---------------------------------------------------------------------

We recently used a Ca^2+^-imaging-based high-throughput screening (HTS) method to identify small-molecule agonists for lysosomal TRPML1 channels ([@bib46]). Although TPCs are Na^+^-selective channels with limited Ca^2+^ permeability ([@bib7]; [@bib16]; [@bib24]; [@bib45]), in a number of cell-based studies, TPCs reportedly mediate Ca^2+^ release from lysosomes ([@bib4]; [@bib5]; [@bib19]; [@bib30]; [@bib34]; [@bib36]; [@bib51]), and it is conceivable that the small Ca^2+^-permeability of TPCs, or activation of Na^+^-dependent Ca^2+^ flux mechanisms (e.g., Na^+^-Ca^2+^ exchanger) secondary to Na^+^ flux may be sufficient to elevate intracellular Ca^2+^. We thus screened HEK293 cells stably expressing human TPC2 (hTPC2) channels with the Library of Pharmacologically Active Compounds (LOPAC) ([@bib26]), the same library of chemicals that were previously tested on TRPML1 channels. Among the positive hits, 23 compounds induced Ca^2+^ increases in TPC2 stable cells ([Figure 1A and B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), but not in cells stably expressing TRPML1^4A^ (a surface-expressing mutant TRPML1 \[[@bib42]\]) channels (data not shown).

![Screening of small-molecule agonists of TPC2.\
(**A**) High-throughput screening of the LOPAC library with Fluo-4 Ca^2+^ imaging in HEK293 cells stably expressing hTPC2 (Dryad, <http://doi.org/10.5061/dryad.s5f6j9h>). Each trace represented the average Ca^2+^ response to individual LOPAC compound. Only positive hits confirmed with electrophysiology were color-coded. (**B**) An example of a positive responder (chlorpromazine, CPZ), which elevated intracellular Ca^2+^ levels at the concentration of 46 µM. Note a similar response was seen with a repeated (re) drug application. (**C**) Representative whole-cell currents in a HEK293 cell upon bath application of clomipramine (100 µM). Both pipette and bath solutions contained symmetric 150 mM Na^+^. Currents were elicited by repeated voltage ramps (−140 to +100 mV; 200 ms) with a 4 s inter-step interval. Holding potential (HP) = 0 mV. (**D**) Representative TPC2-mediated currents (*I*~[TPC2]{.smallcaps}~) activated by clomipramine (100 µM; LyNa-VA1.1) in a HEK293 cell transfected with a surface-expressing mutant TPC2 channel (EGFP-TPC2^LL/AA^; [@bib45]). (**E**) Dose-dependent activation of TPC2 by [Ly]{.ul}sosomal [Na]{.ul}^+^ channel [V]{.ul}oltage-dependent [A]{.ul}ctivators (LyNa-VAs). (**F**) The effect of clomipramine (100 µM) on surface-expressing mutant TRPML1 channels (TRPML1^4A^; [@bib42]). (**G**) Summary of clomipramine effects on whole-cell *I*~[TPC2-LL/AA]{.smallcaps}~ and *I*~[TRPML1-4A]{.smallcaps}~. Individual data and Mean ± S.E.M are presented. \*\*, p\<0.01. (**H**) Activation of *I*~[TPC2]{.smallcaps}~ by LyNa-VA1.2 and [Ly]{.ul}sosomal [Na]{.ul}^+^ channel [A]{.ul}gonist 1 (LyNA1; see [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Individual data for (**A**), (**E**) and (**G**) are presented in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
Figure 1---source data 1.Screening of small-molecule agonists of TPC2.](elife-51423-fig1){#fig1}

Tri-cyclic anti-depressants (TCAs) as TPC2 agonists {#s2-2}
---------------------------------------------------

To our surprise, 5 out of the 23 compounds are well characterized as tri-cyclic anti-depressants (TCAs), which are believed to act on neurotransmitter transporters or voltage-gated Na^+^ channels ([@bib11]; [@bib33]). We therefore characterized the responses of TPC2 channels to TCAs in detail using electrophysiological methods. We first performed whole-cell recordings in HEK293 cells that were transfected with surface-expressed TPC2 mutant channels (TPC2-L^11^L^12^-AA; abbreviated as TPC2^LL/AA^ hereafter). No functional difference was noted between wild-type (WT) TPC2 and TPC2^LL/AA^ channels in terms of channel permeation and gating properties ([@bib45]). To facilitate the detection of TPC2-specific currents, we used symmetric Na^+^ solutions in the bath (extracellular) and pipette (cytosolic) solutions ([@bib45]). All five TCAs robustly and rapidly activated whole-cell currents in TPC2^LL/AA^-expressing cells ([@bib45]), but not in non-transfected HEK293 cells ([Figure 1C and D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B--D](#fig1s1){ref-type="fig"}, [Table 1](#table1){ref-type="table"}, and [Table 1---source data 1](#table1sdata1){ref-type="supplementary-material"}).

###### Summary of electrophysiology-based screening of TPC agonists.

Based on chemical structures, LyNa-VAs were divided into two groups: LyNa-VA1.x and LyNa-VA2.x. EC~50~ and the average TPC2 currents (*I*~[TPC2]{.smallcaps}~) were calculated based on 3--5 whole-cell or whole-endolysosome recordings (see individual data in [Table 1---source data 1](#table1sdata1){ref-type="supplementary-material"}) for each LyNa-VA, respectively.

Table 1---source data 1.Electrophysiology-based screening of TPC agonists.

  ------------------------------------------------------------------------------------------------
  LyNa-VAs     Chemical name     Structure                    EC~50~ (μM)\*   *I*~TPC2~ (pA)\*\*
  ------------ ----------------- ---------------------------- --------------- --------------------
  LyNa-VA1.1   Clomipramine      ![](elife-51423-inf1.jpg)\   43 ± 2          945 ± 111

  LyNa-VA1.2   Desipramine       ![](elife-51423-inf2.jpg)\   87 ± 8          1120 ± 94

  LyNa-VA1.3   Imipramine        ![](elife-51423-inf3.jpg)    112 ± 1         433 ± 94

  LyNa-VA1.4   Amitriptyline     ![](elife-51423-inf4.jpg)\   102 ± 3         876 ± 196

  LyNa-VA1.5   Nortriptyline     ![](elife-51423-inf5.jpg)\   52 ± 10         1916 ± 361

               Carbamazepine     ![](elife-51423-inf6.jpg)\   No activation   No activation

  LyNa-VA2.1   Chlorpromazine    ![](elife-51423-inf7.jpg)\   60 ± 2          1101 ± 508

  LyNa-VA2.2   Triflupromazine   ![](elife-51423-inf8.jpg)\   63 ± 2          984 ± 294

               Phenothiazine     ![](elife-51423-inf9.jpg)\   No activation   No activation
  ------------------------------------------------------------------------------------------------

^\*^Data were obtained from whole-cell recordings at −140 mV.

^\*\*^Data were obtained from whole endolysosome recordings with 100 µM of LyNa-VAs at −120 mV.

We then extended detailed analyses to other known TCAs ([Table 1](#table1){ref-type="table"}). Of them, Clomipramine activated whole-cell TPC2^LL/AA^-mediated strongly rectifying currents (*I*~TPC2-LL/AA~) with an EC~50~ of 43 ± 2 μM (n = 4 patches) ([Figure 1D and E](#fig1){ref-type="fig"}, and [Table 1](#table1){ref-type="table"}). Given the apparent voltage-dependent gating described below, we referred to Clomipramine as [Ly]{.ul}sosomal [Na]{.ul}^+^ channel [V]{.ul}oltage-dependent [A]{.ul}ctivator 1.1 (LyNa-VA1.1). Another structurally different TCA, Chlorpromazine, had an EC~50~ of 60 ± 2 μM (n = 4 patches), and was referred to as LyNa-VA2.1 ([Figure 1E](#fig1){ref-type="fig"}, [Table 1](#table1){ref-type="table"}, and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Other TPC-activating TCAs were referred to as LyNa-VA1.x or LyNa-VA2.x, respectively, based on the structural similarity ([Table 1](#table1){ref-type="table"}). In contrast, no significant activation was seen with Carbamazepine or Phenothiazine, tricyclic drugs without the aliphatic chain ([Table 1](#table1){ref-type="table"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). All TCA-induced currents exhibited strong voltage-dependence and inward rectification, which resembled TRPML1-mediated currents (*I*~TRPML1~) ([@bib42]). However, none of the TCAs had any activation effect on *I*~TRPML1~ ([Figure 1F and G](#fig1){ref-type="fig"}). Taken together, these results suggested that TCAs may function as small-molecule agonists of TPC2 channels.

In a separate screen, we identified another compound (Riluzole, see [Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}) that showed striking differences from the responses elicited by TCAs. Riluzole, an FDA-approved amyotrophic lateral sclerosis drug that is known to modulate voltage-gated Na^+^ channels ([@bib27]), activated large and linear whole-cell currents in TPC2^LL/AA^-expressing HEK293 cells ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), but not in non-transfected HEK293 cells. Given its lack of the voltage-dependence, Riluzole was referred to as [Ly]{.ul}sosomal [N]{.ul}a^+^ channel [A]{.ul}gonist 1 (LyNA1). Hence, more than one agonist-specific gating (voltage-dependent and voltage-independent) mechanism may co-exist within one channel protein.

TCAs activate lysosomal TPC2 channels {#s2-3}
-------------------------------------

TCAs, with a general structure of an aromatic greasy core and an aliphatic chain containing a terminal amine, are lysosomotropic compounds that are known to be highly accumulating in the lysosomes due to proton trapping ([@bib2]). We next tested the effects of LyNa-VAs in hTPC2-transfected Cos1 and HEK293 cells using whole-endolyosome patch-clamp. Cells were pretreated with vacuolin-1 (1 µM) that can selectively increase the size of late endosomes and lysosomes (LELs) up to 5 μm ([@bib13]). The enlarged endolysosomes were manually isolated and then patch clamped in the whole-endolysosome configuration ([@bib13]). In TPC2-positive enlarged LELs isolated from transfected Cos1 cells, little or no basal whole-endolysosome currents were seen under symmetric (pipette/luminal and bath/cytosolic) Na^+^ solutions ([Figure 2A](#fig2){ref-type="fig"}). Consistent with our previous studies, bath application of PI(3,5)P~2~, the endogenous agonist of TPCs ([@bib45]), activated a large whole-endolysosome *I*~TPC2~ with linear I-V ([Figure 2B and E](#fig2){ref-type="fig"}). Both LyNa-VAs and LyNA1 readily activated *I*~TPC2~, although the I-Vs were dramatically different ([Figure 2C, D and E](#fig2){ref-type="fig"}, and [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}). In contrast, no current activation was seen for LyNa-VAs or LyNA1 in TRPML1-transfected cells ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Both LyNa-VAs and LyNA1 activated whole-endolysosome *I*~TPC~ in WT HAP1 cells, but not HAP1 cells lacking *TPC1* or *TPC2* (*TPC1^−/−^/TPC2^−/−^*, TPC1/2 DKO; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), suggesting that the activation effects of both TCAs and LyNA1 on TPCs are specific. In addition, robust activation of *I*~TPC2~ in the whole-cell configuration with agonists being applied from the extracellular side (analogous to the luminal side in the lysosome), as well as in the inside-out ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}) and whole-endolysosome configurations with agonists being applied from the cytosolic side, suggests that LyNa-VAs and LyNA1 are likely to be membrane permeable, activating TPC2 via direct agonist binding. As the channel activation in the whole-cell recordings was significantly slower, that is longer latency and time course of activation, compared to the inside-out and whole-endolysosome recordings (see [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), the action site of LyNa-VAs is likely to be either intracellular or more accessible from the intracellular side.

![LyNa-VAs activate lysosomal TPC2 channels in a voltage-dependent manner.\
(**A**) Representative basal *I*~[TPC2]{.smallcaps}~ step currents elicited by a voltage step protocol in the whole-endolysosome (EL) configuration. Voltage steps from −140 to 100 mV with a voltage increment (∆V) of 20 mV for 0.5 s were used to elicit *I*~[TPC2]{.smallcaps}~ in A-D. HP = 0 mV. Unless otherwise indicated, symmetric (bath/cytosol vs pipette/lumen) Na^+^ (150 mM) solutions were used for all whole-endolysosome recordings, and PI(3,5)P~2~ (0.3 µM), LyNa-VA1.2 (100 µM), and LyNA1 (300 µM) were bath- applied to induce *I*[~TPC2~.]{.smallcaps} (**B--D**) Representative *I*~[TPC2]{.smallcaps}~ step currents activated by PI(3,5)P~2~ (**B**), LyNa-VA1.2 (**C**), and LyNA1 (**D**). (**E**) Representative normalized I-V plots based on the instantaneous currents activated by various agonists. (**F**) Rectification index, calculated as the ratio of the current amplitudes between +80 and −80 mV, of PI(3,5)P~2~-, LyNa-VA1.2-, and LyNA1- activated *I*~[TPC2]{.smallcaps}~. (**G**) The inactivation of *I*~[TPC2]{.smallcaps}~ at −120 mV was quantified as the ratio of current amplitudes at 10 *vs.* 500 ms, based on step currents in **B**, (**C**) and D. (**H**) Voltage steps from −120 to 100 mV (∆V = 20 mV) for 1 s were used to elicit tail currents at −120 mV shown in (**I**) and (**J**). (**I**) The tail currents of PI(3,5)P~2~- evoked whole-endolysosome *I*[~TPC2~.]{.smallcaps} (**J**) The tail currents of LyNa-VA1.2- activated whole-endolysosome *I*~[TPC2]{.smallcaps}~. Arrows in (**I**) and (**J**) indicate where the currents were measured to calculate the channel conductance (G = I/V). (**K**) Normalized G-V curves of PI(3,5)P~2~- and LyNa-VA1.2- activated *I*[~TPC2~.]{.smallcaps} LyNa-VA1.2 activated *I*~[TPC2]{.smallcaps}~ in a voltage dependent manner with a V~1/2~ = −20.3 ± 3.5 mV (n = 5 patches). For panels **F** and **G**, individual data and Mean ± S.E.M. are presented. \*\*\*, p\<0.001. Individual data for (**F**) and (**G**) are presented in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
Figure 2---source data 1.The inactivation of *I*~[TPC2]{.smallcaps}~ and rectification index of TPC2.](elife-51423-fig2){#fig2}

Activation of TPCs by LyNa-VAs shows strong voltage dependence {#s2-4}
--------------------------------------------------------------

Despite the fact that TPCs have two S4 domains that act as voltage sensors in many voltage gated channels ([@bib40]), the responses of TPC2 to PI(3,5)P~2~ and LyNA1 were voltage independent, with large currents at both positive and negative voltages ([Figure 2B, D and E](#fig2){ref-type="fig"}). In contrast, TPC2 currents activated by TCAs were strongly voltage-dependent, in both whole-cell and whole-endolysosome recordings, no matter whether the currents were elicited by a voltage ramp or a series of voltage steps (see [Figure 2C and E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In both whole-cell and whole-endolysosome configurations, TCA-activated step currents displayed prominent inactivation and strong inward rectification ([Figure 2C, E and F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), suggesting the existence of voltage-dependent activation and/or inactivation gating processes. The steady-state voltage dependence of the responses to all 7 TCAs were qualitatively similar. A convenient way to quantitatively summarize the voltage dependence of the TCA responses was to calculate the rectification ratio ($\frac{I@ + 80mV}{I@ - 80mV}$ ), which was 1.00 ± 0.06 (n = 4 patches) for activation by PI(3,5P)~2~, 0.93 ± 0.03 for LyNA1 (n = 4), but only 0.10 ± 0.03 for LyNa-VA1.2 (n = 6, [Figure 2F](#fig2){ref-type="fig"}).

Under the voltage-step protocols, LyNa-VA-activated *I*~TPC2~ exhibited substantial time-dependent inactivation at negative voltages ([Figure 2C and G](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). This could be conveniently characterized by two parameters: the amount of current decline at steady state ($\frac{I@500ms}{I@10ms}$) and the time constant (τ) of the decay of current. There was no inactivation with ratio near 1.0 at all potentials when the agonist was PI(3,5)P~2~ or LyNA1, but the ratio was 0.6 or less for all the active TCAs tested at −120 mV; the time constant of inactivation was approximately 300 ms at −120 mV ([Figure 2J](#fig2){ref-type="fig"} a*nd* [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

When we used a tail-current protocol to study the voltage-dependent activation, the activation by LyNa-VA1.2 was strongly dependent on voltage, with a half-maximal activation voltage (V~1/2~) of −20 mV at the concentration of 100 μM ([Figure 2J and K](#fig2){ref-type="fig"}). In contrast, no apparent voltage-dependent activation was seen when whole-endolysosome *I*~TPC2~ was activated by PI(3,5)P~2~ ([Figure 2I and K](#fig2){ref-type="fig"}) or LyNA1. Collectively, LyNa-VAs have manifested multiple aspects of voltage-dependent gating of TPC2 channels.

Synergistic activation of TPC2 by PI(3,5)P~2~ and TCAs {#s2-5}
------------------------------------------------------

PI(3,5)P~2~ reportedly binds to Lys204 and adjacent AA residues to activate TPC2 ([@bib41]). In the cells that were transfected with a PI(3,5)P~2~-insensitive mutant TPC2 channel (K204A) ([@bib41]), LyNa-VA and LyNA1 still robustly activated whole-endolysosome *I*~TPC2~ ([Figure 3A and B](#fig3){ref-type="fig"} a*nd* [Figure 3---figure supplement 1A and B](#fig3s1){ref-type="fig"}). Lysosomal PI(3,5)P~2~ may play a permissive role in TPC activation in intact cells ([@bib36]). Much dramatic LyNa-VA activation was seen in the presence of a low concentration of PI(3,5)P~2~ (50 nM; [Figure 3C and D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), and this synergism was nearly abolished in TPC2^K204A^ mutant channels ([Figure 3C and D](#fig3){ref-type="fig"}). In contrast, an additive but not synergistic activation was observed between LyNA1 and PI(3,5)P~2~ ([Figure 3---figure supplement 1D and E](#fig3s1){ref-type="fig"}).

![Synergistic activation of TPC2 channels by TCAs and PI(3,5)P~2~.\
(**A**) The effects of PI(3,5)P~2~ (0.3 µM) and LyNa-VA1.2 (100 µM) on whole-endolysosome *I*~[TPC2-K204A]{.smallcaps}~ in TPC2^K204A^-transfected HEK293 cells ([@bib41]). (**B**) Comparison effects of LyNa-VA1.2 and PI(3,5)P~2~ on WT and PI(3,5)P~2~-insensitive K204A ([@bib41]) mutant TPC2 channels (also see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). (**C**) The synergistic effects of PI(3,5)P~2~ (50 nM) and LyNa-VA1.1 on whole-endolysosome *I*~[TPC2]{.smallcaps}~ and *I*~[TPC2-K204A]{.smallcaps}~ currents. Data are presented as Mean ± S.E.M (n = 3 patches). (**D**) The summary of EC~50~ of LyNa-VA1.1 with or without PI(3,5)P~2~ for WT and K204A mutant TPC2 channels. (**E, F**) Co-application of PI(3,5)P~2~ (0.3 µM) and LyNa-VA1.1 (50 µM) activated whole-endolysome *I*[TPC]{.smallcaps} in WT (**E**) but not TPC1/2 DKO (**F**) HAP1 cells. Note that the endogenous TPCs were more difficult to activate compared to overexpressed TPCs. (**G**) Summary of LyNa-VA1.1 effects on whole-endolysome *I*~[TPC]{.smallcaps}~ in WT and TPC1/2 DKO cells. For panels B, D and F, individual data and Mean ± S.E.M are presented. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; N.S., no significance. Individual data for (**B--D**) and (**G**) are presented in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}.\
Figure 3---source data 1.Synergistic activation of TPC2 channels by TCAs and PI(3,5)P~2~.](elife-51423-fig3){#fig3}

Although LyNa-VAs weakly activated endogenous TPC currents, in the presence of PI(3,5)P~2~, more robust activation was seen ([Figure 3E and G](#fig3){ref-type="fig"}). In contrast, no measurable whole-endososome *I*~TPC~ was seen in TPC1/2 DKO HAP1 cells even in the presence of both PI(3,5)P~2~ and LyNa-VAs ([Figure 3F and G](#fig3){ref-type="fig"}). Collectively, these results suggested that LyNa-VAs activated or modulated TPC2 via a unique, PI(3,5)P~2~-independent but voltage-dependent mechanism.

Voltage-dependent activation of TPC1 by TCAs {#s2-6}
--------------------------------------------

In contrast to TPC2, which produces little or no current at any potential under basal conditions, yet a large, voltage-independent conductance increases in the presence of PI(3,5)P~2~, TPC1 shows substantial voltage-dependent currents in the absence of any exogenous agonist ([@bib7]; [@bib15]). It was therefore of interest to explore whether TCAs/LyNa-VAs could also act on TPC1. To investigate this, we used two different voltage paradigms. First, when membrane voltage was stepped to various test potentials after a prolonged pre-pulse to +80 mV and the currents were compared to the basal currents, LyNa-VA1.1 produced a profound suppression of outward currents at potentials positive to E~rev~ (\~0 mV), and a substantial enhancement of inward currents negative to E~rev~ ([Figure 4A and B](#fig4){ref-type="fig"}). Hence, upon LyNa-VA1 activation, the I-V of TPC1 completely reversed from strong outward rectification to strong inward rectification ([Figure 4B and C](#fig4){ref-type="fig"}). Intriguingly, unlike LyNa-VA1.1 and LyNa-VA1.2, which activated inward *I*~TPC2~ with EC~50~s within micromolar ranges, both LyNa-VA2.1 and LyNA1 inhibited *I*~TPC1~ ([Figure 4D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Second, we used a tail current paradigm to measure the amplitude of the peak inward current at −120 mV following prolonged steps to various potentials ([Figure 4E](#fig4){ref-type="fig"}). The effect of LyNa-VA1.1 was to shift the midpoint of activation voltage (V~1/2~) by −65 mV as compared to the basal condition, and to slow down the deactivation time course ([Figure 4E--F](#fig4){ref-type="fig"}).

![Activation of lysosomal TPC1 channels by LyNa-VAs.\
(**A**) Whole-endolysosome TPC1 current (*I*~[TPC1]{.smallcaps}~) was activated by LyNa-VA1.1 (right) and elicited by a voltage step protocol (left), in which a preconditioning voltage (80 mV, 0.3 s) was applied before voltage steps starting from −140 to 100 mV (0.8 s, ∆V = 20 mV). HP = 0 mV. Unless otherwise indicated, symmetric 150 mM Na^+^ solutions were used for all whole-endolysosome recordings, and LyNa-VA1.1 (100 µM) was bath-applied[.]{.smallcaps} (**B**) I-V plots of basal- and LyNa-VA1.1-induced *I*[~TPC1~,]{.smallcaps} which were recorded from the same vacuole. Dotted lines in A indicate where the currents were measured. (**C**) Summary of rectification index of basal and LyNa-VA1.1-induced *I*~[TPC1]{.smallcaps}~. Individual data and Mean ± S.E.M are presented. \*\*\*, p\<0.001. (**D**) Does-dependent activation or inhibition of TPC1 by LyNa-VA1.1, LyNa-VA1.2, and LyNa-VA2.1. Data are presented as Mean ± S.E.M (n = 3 patches). (**E**) The effects of LyNa-VA1.1 on *I*~[TPC1]{.smallcaps}~ tail currents at −120 mV. The voltage protocol that elicited *I*~[TPC1]{.smallcaps}~ tail currents was shown in [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}. (**F**) The effects of LyNa-VA1.1 on the G-V curves of *I*~[TPC1]{.smallcaps}~ (n = 4--5 patches). (**G**) Normalized I-V plots of basal voltage-dependent currents in WT TPC1- and TPC1^R540I^-transfected cells. (**H**) The basal and LyNa-VA1.1-activated *I*~[TPC1-R540I]{.smallcaps}~ step currents, which were recorded from the same vacuole. Individual data for (**C**), (**D**) and (**F**) are also presented in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
Figure 4---source data 1.Activation of lysosomal TPC1 channels by LyNa-VAs.](elife-51423-fig4){#fig4}

The S4 segments of TPC1 and TPC2 contain several positively-charged AA residues, which were believed to serve as voltage sensors in mediating TPC1- but not TPC2-specific activation ([@bib40]). It was recently reported that the R540I mutation, which removes a positive charge in the second putative voltage-sensing 'S4-type' helix, abolished TPC1 activation by membrane depolarization ([@bib40]). However, in our hands, depolarization still robustly activated voltage-dependent currents in the whole-endolysosomes of hTPC1^R540I^ -expressing cells ([Figure 4G and H](#fig4){ref-type="fig"}). When LyNa-VA1.1 was tested on endolysosomes overexpressing TPC1^R540I^, there was also a dramatic enhancement of inward currents at negative potentials indicative of a substantial negative shift in the V~1/2~ of voltage activation ([Figure 4H](#fig4){ref-type="fig"}). Finally, when exposed to PI(3,5)P~2~, *I*~TPC1~ showed a large enhancement at negative potentials indicative of a negative shift in the V~1/2~ of activation, while TPC1^R540I^ -positive endolysosomes showed large currents at all potentials ([Figure 4---figure supplement 2A, B and C](#fig4s2){ref-type="fig"}). The charge-introducing mutation at Ile551 of TPC2 ([@bib41]), the equivalent site of TPC1^R540^, conferred a voltage-dependence to the mutant channel but failed to affect LyNa-VA1.2 activation ([Figure 4---figure supplement 2D and E](#fig4s2){ref-type="fig"}). Put together, these results suggested that whereas the S4 voltage-sensing domains may play a modulatory role, there exist intrinsic or extrinsic voltage-sensing mechanisms elsewhere responsible for the voltage-dependent gating of TPCs.

Cationic ion selectivity of TPC2 is not altered by LyNa-VAs and LyNA1 {#s2-7}
---------------------------------------------------------------------

The selectivity filter region in an ion channel is responsible for the selective permeability to one or more ions ([@bib49]). However, it was recently reported that AA residues below the selectivity filter may mediate activation gating of multiple K^+^ channels by small-molecule agonists ([@bib39]). In addition, some voltage sensitivity can be conferred when the permeable ions move through the selectivity filter ([@bib38]). We therefore tested whether TCAs/LyNa-VAs bind to the selectivity filer. Like PI(3,5)P~2~-activated *I*~TPC2~ ([Figure 5A--C and K](#fig5){ref-type="fig"}), LyNa-VA1.2- and LyNA1-induced whole-endolysosome *I*~TPC2~ was highly selective for Na^+^ over K^+^, as substitution of bath/cytoplasmic Na^+^ with K^+^ significantly shifted E~rev~ to more positive values ([Figures 1H](#fig1){ref-type="fig"}, [5D--F and K](#fig5){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Meanwhile, LyNa-VA1.2- and LyNA1-activated *I*~TPC2~ still exhibited low Ca^2+^ permeability ([Figure 5G and K](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), and the P~Ca~/P~Na~ values were similar to those for PI(3,5)P~2~-activated *I*~TPC2~ ([@bib45]) ([Figure 5K](#fig5){ref-type="fig"} **a**nd [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Finally, the N653G mutation, which is known to significantly increase the relative K^+^ permeability of the TPC2 channel ([@bib16]), did not alter the ability of LyNa-VA1.2 to enhance channel activation, but did result in currents elicited by LyNa-VA1.2 that had a much increased relative permeability to K^+^ ([Figure 5I--K](#fig5){ref-type="fig"}). Taken together, these results indicate that the selectivity filter region does not mediate the action of TCAs.

![LyNa-VAs do not change the cationic selectivity of TPC2 channels.\
(**A**) Representative PI(3,5)P~2~-evoked whole-endolysosome *I*~[TPC2]{.smallcaps}~ elicited by a voltage ramp from −120 to 120 mV. The recordings were performed under a bi-ionic condition with 150 (in mM) Na^+^ in the pipette solution and 150 Na^+^ or 150 K^+^ in the bath solution. PI(3,5)P~2~ (0.3 µM) was bath-applied. (**B, C**) Representative PI(3,5)P~2~- evoked *I*~[TPC2]{.smallcaps}~ elicited with voltage steps (−140 mV to 100 mV with a ∆V = 20 mV, 0.5 s) with 150 mM Na^+^ (**B**) or K^+^(**C**) in the bath solution. (**D, E**) Representative LyNa-VA1.2-activated *I*~[TPC2]{.smallcaps}~ step currents. (**F**) Representative I-V plots of LyNa-VA1.2- activated *I*~[TPC2]{.smallcaps}~ measured from the instantaneous currents in (**D**) and (**E**). Note the reversal potentials (E~rev~) of LyNa-VA1.2- activated *I*~[TPC2]{.smallcaps}~ in the presence of Na^+^ or K^+^ bath solution. (**G**) LyNa-VA1.2- activated *I*~[TPC2]{.smallcaps}~ under the bi-ionic conditions of bath/cytosolic Na^+^ and pipette/luminal Ca^2+^. 150 Na^+^ solution contained (in mM) 145 NaCl, 5 NaOH, 20 HEPES, (pH 7.2); isotonic (105 mM) Ca^2+^ solution contained (in mM) 100 CaCl~2~, 5 Ca(OH)~2~, 20 HEPES (pH 7.2). Right panel zoom-in micrograph shows the E~rev~ of LyNa-VA1.2- activated *I*~[TPC2]{.smallcaps}~. (**H--J**) Representative I-V plots of LyNa-VA1.2- evoked *I*~[TPC2-N653G]{.smallcaps}~ (**J**) measured from Na^+^ (**H**) and K^+^ (**I**) bath solution. (**K**) Summary of Na^+^ *vs.* K^+^ /Ca^2+^ selectivity of WT TPC2 and TPC2^N653G^ channels. Individual data and Mean ± S.E.M are presented (also see [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). N.S., no significance.\
Figure 5---source data 1.Ionic selectivity of WT TPC2 and N653G mutant channels.](elife-51423-fig5){#fig5}

Discussion {#s3}
==========

In this study, we report that the voltage dependence, generally thought to be an intrinsic property of an ion channel ([@bib10]; [@bib49]), can be conferred or unmasked by extrinsic agonists in lysosomal TPC channels. What is the origin of agonist-conferred voltage-dependence in the otherwise voltage-independent TPC2 channel? It is possible that the S4 voltage sensors, which are operational in TPC1, might be 'exposed' upon agonist binding. Alternatively, another unidentified 'hidden' intrinsic voltage sensor might be revealed upon agonist binding, a possibility that was supported by the negative results in our targeted mutational analyses of the S4 regions. Additionally, it is recently reported that permeant ions may contribute to the channel's voltage-dependence ([@bib39]). Hence, it is an attractive hypothesis that a gate at the selectivity filter is the molecular target of TCAs to mediate the observed voltage-dependence. However, it remains unknown whether such a 'selectivity filter gate', extensively studied in several other ion channels including CNG channels ([@bib12]), does exist in TPC channels. Nevertheless, although mutational analyses in the selectivity filter or the 'S6 gate' (data not shown) do not seem to affect LyNa-VA activation, given the limitations of targeted mutations, future high-resolution structural studies may be necessary to reveal the TCA-binding sites in the TPC channels, explaining the conferred voltage dependence by TCAs. In addition, the differential effects of LyNa-VAs on TPC1 and TPC2 may also help design future structural-functional studies to reveal the action site of TCAs on TPCs.

Diverse functions have been associated with TPC channels, largely based on genetic manipulations (e.g. KO, knockdown, overexpression) ([@bib14]; [@bib48]). However, the roles of TPCs in some of the proposed functions might be indirect based on the following reasons. First, lysosomal membrane trafficking, for example fusion and fission, has been difficult to study as these functions are interconnected. For instance, a block in membrane fusion may often indirectly affect membrane fission, and vice versa ([@bib48]). In addition, defects in lysosomal membrane trafficking may also affect lysosomal degradation, and degradation products may in turn regulate membrane trafficking ([@bib48]). Second, compensatory changes occur commonly in the genetically-manipulated cells, for example KO or lysosome storage disease (LSD) cells. Hence, it is necessary to develop methods to acutely activate and inhibit lysosomal channels, so that immediate cellular actions of TPC activation can be revealed. Notably, precisely defining TPC's roles in lysosomal Δψ regulation may require real-time monitoring of lysosomal Δψ while acutely activating or inhibiting lysosomal K^+^ and Na^+^ channels ([@bib24]). The identification of membrane-permeable small-molecule TPC agonists has made it feasible for such studies.

TCAs are known to regulate autophagy and lysosome function, but underlying mechanisms are not clear ([@bib43]). For example, in a neuronal model of Huntington disease (HD), TCAs were shown to be neuroprotective by inducing the clearance of misfolded protein aggregates ([@bib43]). Given the proposed roles of TPCs in autophagy and lysosomal membrane trafficking ([@bib14]; [@bib24]), it is likely some of the effects associated with TCAs are mediated by TPCs. The concentrations of TCAs that activate autophagy are lower than those activating TPC channels in the current study ([@bib2]; [@bib11]). However, TCAs, as lysosomotropic compounds, are known to accumulate at high concentrations in the lysosomes ([@bib2]). In addition, the synergistic effects of TCAs with endogenous ligand, for example PI(3,5)P~2~, suggest that the exposure level of TCAs in the brain might be sufficient to cause robust pharmacological actions, much more potently than the efficacies defined in our channel assays. Future cell biological studies utilizing TCAs with TPC KO as negative controls may confirm whether TCAs modulate autophagy and lysosome function through activation of TPCs.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                        Designation                Source or reference                   Identifiers                                                    Additional\
  (species) or\                                                                                                                                                        information
  resource                                                                                                                                                             
  ------------------------------------ -------------------------- ------------------------------------- -------------------------------------------------------------- ----------------------
  Cell line (*Homo sapiens*)           HEK293                     ATCC                                  RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)     

  Cell line (*Homo sapiens*)           HAP1                       Horizon Discovery                     Cat. \#: C631                                                  

  Cell line (*Chlorocebus aethiops*)   Cos1                       ATCC                                  RRID:[CVCL_0223](https://scicrunch.org/resolver/CVCL_0223)     

  Recombinant DNA reagent              pEGFP-C2-TPC2\             [@bib45]                                                                                             
                                       (plasmid)                                                                                                                       

  Recombinant DNA reagent              pEGFP-C2-TPC1\             [@bib45]                                                                                             
                                       (plasmid)                                                                                                                       

  Sequence-based reagent               TPC1-sgRNA                 This paper                            sgRNA                                                          CTTGCAGTACTTCAGCACCC

  Sequence-based reagent               TPC2-sgRNA                 This paper                            sgRNA                                                          CCCCAGCGTCGGGCTGCTGC

  Sequence-based reagent               TPC1-fw                    This paper                            PCR primers                                                    ATGGCCCAGACATGTGACTC

  Sequence-based reagent               TPC1-re                    This paper                            PCR primers                                                    TGCCTGTCTCCATCCTCTCA

  Sequence-based reagent               TPC2-fw                    This paper                            PCR primers                                                    TGAGCTGAGCATGAGGCAAG

  Sequence-based reagent               TPC2-re                    This paper                            PCR primers                                                    AAAGGACAAGTGGCCCTGAG

  Chemical compound, drug              Desipramin hydrochloride   Sigma                                 Cat. \#: D3900                                                 

  Chemical compound, drug              Carbamazepine              Sigma                                 Cat. \#: C4024                                                 

  Chemical compound, drug              monensin                   Sigma                                 Cat. \#: M5273                                                 

  Chemical compound, drug              ionomycin                  Sigma                                 Cat. \#: I0634                                                 

  Chemical compound, drug              Clomipramine               Cayman Chemical                       Cat. \#: 15884                                                 

  Chemical compound, drug              Imipramine                 Cayman Chemical                       Cat. \#: 15890                                                 

  Chemical compound, drug              Amitriptyline              Cayman Chemical                       Cat. \#: 15881                                                 

  Chemical compound, drug              Nortriptyline              Cayman Chemical                       Cat. \#: 15904                                                 

  Chemical compound, drug              Phenothiazine              NCATS                                 CAS: 92-84-2                                                   

  Chemical compound, drug              Triflupromazine            NCATS                                 CAS: 146-54-3                                                  

  Chemical compound, drug              Chlorpromazine             Cayman Chemical                       Cat. \#: 16129                                                 

  Chemical compound, drug              ML-SA1                     Princeton BioMolecular Research Inc   Cat. \#: OSSK_389119                                           

  Chemical compound, drug              PI(3,5)P~2~                Echelon Biosciences                   Cat. \#: P-3508                                                

  Chemical compound, drug              vacuolin-1                 Calbiochem                            Cat. \#: 673000                                                

  Software, algorithm                  pClamp                     pClamp                                RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Molecular biology {#s4-1}
-----------------

All TPC1 and TPC2 mutants were generated with a site-directed mutagenesis kit (Qiagen) using EGFP- human TPC1 and TPC2 as the templates. All constructs were confirmed by DNA sequencing.

Mammalian cell lines {#s4-2}
--------------------

Cos1 (ATCC, CRL-1650, passage number 8--15) and HEK293 (ATCC, CRL-1573, passage number 8--15) cells were cultured in DMEM with 10% fetal bovine serum (FBS). HAP1 (Horizon Discovery, human HAP1 parental cell line, passage number 5--15) cells were maintained in IMDM with 10% FBS. Immortalized cell lines (Cos1, HEK293 and HAP1) were cultured following standard tissue culture protocols, and were tested negative for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit Assay (Lonza). HEK293 cells are on the list of frequently misidentified or cross-contaminated cell lines, but were only used for the overexpression experiments. Cells were transfected with Lipofectamine 2000 (Invitrogen). After culture media were refreshed 18--24 hr post-transfection, cells were used for the electrophysiological assays 24--36 hr post-transfection.

TPC1/TPC2 DKO HAP1 cells {#s4-3}
------------------------

TPC1 and TPC2 CRISPR KO cells were generated in HAP1 cells using the CRISPR/Cas9 system. The TPC1 sequence (5\'cttgcagtacttcagcaccc3\', TPC1-sgRNA) and TPC2 sequence (5\'ccccagcgtcgggctgctgc3\', TPC2-sgRNA) were targeted with pSpCas9 (BB)−2A-puro vector (Addgene). HAP1 cells were co-transfected with TPC1 and TPC2-sgRNA expressing vector in the presence of Lipofectamine 2000 (In vitrogen) and selected with 2 μg/ml puromycin for 48 hr. The remaining cells were trypsinized and seeded into 96-well plate after a limiting dilution. When single cell clones were established, their genomic DNAs were extracted and amplified with following primers: TPC1-fw: 5'atggcccagacatgtgactc3', TPC1-re: 5' tgcctgtctccatcctctca3'; TPC2-fw: 5'tgagctgagcatgaggcaag3', TPC2-re: 5' aaaggacaagtggccctgag3'. The PCR amplicons were then sequenced to confirm the intended genetic disruption. The TPC1/TPC2 DKO cells harboring an insert of one nucleotide (A) in the TPC1 sequence and a deletion of ten nucleotides in the TPC2 sequence, respectively, were used in the present study.

LOPAC high-throughput screening {#s4-4}
-------------------------------

Ca^2+^ imaging-based HTS using the Library of Pharmacologically Active Compounds (LOPAC)1280 collection (Sigma) was conducted as described previously ([@bib26]). Briefly, HEK293 cells stably expressing TPC2 and TRPML1 were loaded with a Ca^2+^ detection dye (Fluo-4). The kinetic of Ca^2+^ flux was measured using a kinetic plate reader FDSS-7000 ([@bib26]). The FDSS-7000 had an on-board 1536 pintool that was used to transfer 23 nl of a compound to the assay plate ([@bib26]). All of the compounds were dissolved in 100% DMSO. Hence, transferring 23 nl of a compound to a well containing 5 μl of the culture medium would result in a final concentration of DMSO of \~0.5%. The final concentrations of the LOPAC compounds in each were 0.003, 0.015, 0.074, 0.37, 1.84, 9.2, and 46 μM, respectively. Compounds that were positive in the TPC2 assay, but not in the TRPML1 assay, were considered to be positive hits for potential TPC2 agonists.

Whole-cell electrophysiology {#s4-5}
----------------------------

Whole-cell recordings were performed using pipette electrodes with resistance of 3--5 MΩ. Unless otherwise stated, both pipette and bath solutions contained (in mM): 145 NaOH, 5 NaCl, 20 HEPES, pH 7.2 (adjusted with methanesulfonic acid). All bath solutions were applied via a perfusion system that allowed complete solution exchange within a few seconds. Data were collected using an Axopatch 200A patch clamp amplifier, Digidata 1440, and pClamp 10.2 software (Axon Instruments). Whole-cell currents were digitized at 10 kHz and filtered at 2 kHz. All experiments were conducted at room temperature (21--23°C), and all recordings were analyzed with pClamp 10.2, and Origin 8.0 (OriginLab, Northampton, MA).

Whole-endolysosome electrophysiology {#s4-6}
------------------------------------

Endolysosomal electrophysiology was performed in isolated enlarged endolysosomes using a modified patch-clamp method ([@bib13]). Cells were treated with 1 μM vacuolin-1, a lipid-soluble polycyclic triazine that can selectively increase the size of endosomes and lysosomes ([@bib18]), for at least 1 hr and up to 12 hr. Whole-endolysosome recordings were performed on manually isolated enlarged endolysosomes ([@bib45]). In brief, a patch pipette was pressed against a cell and quickly pulled away to slice the cell membrane. Enlarged endolysosomes were released into a dish and identified by monitoring EGFP-TPC1/2 or the mCherry-TPC1/2 fluorescence. After formation of a gigaseal between the patch pipette and the enlarged endolysosome, capacitance transients were compensated. Voltage steps of several hundred mVs with millisecond duration were then applied to break into the vacuolar membrane. The whole-endolysosome configuration was verified by the re-appearance of capacitance transients after break-in.

Unless otherwise stated, both bath (internal/cytoplasmic) and pipette solutions contained (in mM): 145 NaOH, 5 NaCl, 20 HEPES, pH 7.2 (adjusted with methanesulfonic acid). 150 K^+^ solution contained (in mM): 145 KOH, 5 KCl, 20 HEPES, pH 7.2 (adjusted with methanesulfonic acid). Data were collected using an Axopatch 200A patch clamp amplifier, Digidata 1440, and pClamp 10.2 software (Axon Instruments). Whole-endolysosome currents were digitized at 10 kHz and filtered at 2 kHz. All experiments were conducted at room temperature (21--23°C), and all recordings were analyzed with pClamp 10.2, and Origin 8.0 (OriginLab, Northampton, MA). The permeability to cations (relative to P~Na~) was estimated based on following equations ([@bib22]) and E~rev~ measurement under bi-ionic conditions:$${}P_{X}/P_{Na} = \gamma_{Na}/\gamma_{X}\,\left\{ {\lbrack Na^{+}\rbrack_{Luminal}\,/\,\lbrack X^{+}\rbrack_{Cytoplasmic}} \right\}\left\{ {exp(R_{rev}F/RT)} \right\}$$$${}P_{Ca}/P_{Na} = \gamma_{Na}/\gamma_{Ca}\,\left\{ {\lbrack Na^{+}\rbrack_{Cytoplasmic}\,/\,\lbrack 4\lbrack Ca^{2 +}\rbrack_{Luminal}} \right\}\left\{ {exp(E_{rev}F/RT)} \right\}\left\{ {1 + exp(E_{rev}F/RT)} \right\}$$where R, T, F, E~rev~, and γ are, respectively, the gas constant, absolute temperature, Faraday constant, reversal potential, and activity coefficient. The liquid junction potentials were measured and corrected as described ([@bib31]).

Data analysis {#s4-7}
-------------

Data are presented as the mean ± standard error of the mean (S.E.M). Statistical comparisons were made using analysis of variance (ANOVA). A p value \< 0.05 was considered statistically significant.
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Acceptance summary:

The function of lysosomes is more and more being linked to several important normal and pathological physiological states. Several of these functions are linked to ion transport mechanisms mediated by ion channels that are not completely understood. In this manuscript, the authors have identified small-molecule agonist for the lysosomal two-pore channels, TPC1 and TPC2. Strikingly these agonist are tricyclic compounds that have traditionally been used as antidepressants. This is a clear example of re-purposing of clinically-relevant compounds and it also open the window to understanding secondary effects of these drugs that cannot be explained by their classically described actions. Lysosomal ion channels are notoriously difficult to study, given their location and poorly characterized biophysical properties. The findings in this manuscript also suggest that these compounds could help identify drug-specific modes of activation in two-pore channels. Given the growing recognition of the importance of lysosomes in several diseases, this findings are of general interest to clinicians and basic scientist alike. The compounds identified and initially characterized here should make the task of understanding the physiology of TPC1 and TPC2 channels a little easier.

**Decision letter after peer review:**

Thank you for submitting your article \"Agonist-specific voltage-dependent gating of lysosomal two-pore Na^+^ channels\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Leon D Islas as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Shmuel Muallem (Reviewer \#2); Tinatin Brelidze (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The paper by the Xu group describes the novel finding that tricyclic anti-depressants, a major class of clinically relevant drugs, also behave as activators of the two-pore, Na-selective lysosomal ion channels TPC1 and TPC2. The authors show that these drugs induce voltage-dependent and voltage-independent modes of activation of these channels. These findings are relevant because they provide a possible new framework for the development of new TPC-selective activators (and possibly, inhibitors) with increased potency. These drugs offer the possibility of having an increased toolset for the study of these class of channels and open the door for understanding side effects and off-target effects of tricyclic anti-depressants. The reviewers are very enthusiastic about the manuscript and offer the following comments that the authors should attend.

Major comments:

1\) While the authors showed that the effect is specific to TPC channels the effect may not be direct and might be mediated by a signaling cascade. This could be determined by recording currents from excised patches in the absence and presence of the agonists. In addition, the comparison of the time-course of activation for inside-out and whole cell or outside-out patches may suggest if the agonist binding site is extracellular or intracellular.

2\) For pharmacological comparisons it would be useful to determine the EC~50~ for TPC1 and at least a few of the identified agonists.

3\) Figure 3C could be strengthened by including dose-response data for K204 mutant. It is conceivable that the agonists might activate or expose additional PIP2 sites, distinct from the one destabilized by the K204A mutation. The dose-response experiments might reveal this possibility.

4\) The effect of Riluzole is also very interesting and could be considered in more depth. The authors have not described the effect of Riluzole on TPC1 channels. Is it still voltage-independent? It is important to know if the mechanism of this agonist action is similar in the two channels, as it might help in identifying the molecular determinants of the effect. It also would be of interest to investigate the effect of Riluzole on TPC2 and R540I TPC1 mutant channels in the presence of PIP2. Both agonists show linear activation with voltage and therefore there is a possibility that they might be competitive.

5\) Since the hTPC2 currents activated by TCAs are so different (Figure 2C), the possibility exists that channels other than TPC2 mediate these currents. The authors should endeavor to show that an hTPC2-specific blocker also blocks TCA-activated currents.

6\) In the subsection "Cationic ion selectivity of TPC2 is not altered by LyNa-Vas", the authors make the argument that to probe if TCAs bind to the selectivity filter, they investigate possible changes in ion selectivity. They find that there are no changes in selectivity in the presence of TCAs and therefore these drugs do not bind at the selectivity filter. This argument is flawed; there is no reason to think that a drug binding in or near the selectivity filter necessarily alters the selectivity to ions.

7\) Further, the authors mention a \"selectivity gate\" do they mean \"gate at the selectivity filter\"? If so, there is no evidence that TPC channel\'s gating occurs at the selectivity filter, like in CNG cation channels. It is sometimes wrongly assumed that all ions have gating at a bundle crossing (S6 gate) *and* at the selectivity filter.

8\) The last paragraph of the Discussion presents some discussion of the possible consequences of this newly described interaction between TCAs and lysosomal cation channels, however, there is no discussion of the possible mechanism of voltage-dependent gating induced in TPC channels and this is a major point of the manuscript.

9\) In Figure 1E, it is surprising that the magnitude of the currents is so similar between cells to have the size of errors presented. Surely there should be a large variability in the levels of expression. Please present all comparisons between currents as normalized current density (current/capacitance).

10.7554/eLife.51423.sa2

Author response

Although the reviewers found our work interesting, they have made several specific suggestions to improve the paper. To address the reviewers' concerns, we have performed a number of new experiments. The most significant changes are highlighted in the summary paragraphs below, and all other concerns are addressed in the point-by-point response.

First, in response to the reviewers' suggestions, we performed additional new experiments to systematically investigate the effects of LyNA1 (the voltage-independent synthetic agonist) on both TPC1 and TPC2 channels, especially regarding the ion selectivity and synergistic activation with PI(3,5)P~2~. Unlike LyNa-VAs (the voltage-dependent synthetic agonists), LyNA1 activated TPC2 currents (*I*~TPC2~) in a voltage-independent manner (Figure 2D, 2E) through an additive but not synergistic mechanism to PI(3,5)P~2~ (new Figure 3---figure supplement 1D, E). In contrast, *I*~TPC1~ was inhibited by LyNA1 (new Figure 4---figure supplement 1B). Neither LyNa-VAs nor LyNA1 affected the Na^+^-selectivity of TPC channels (Figure 5K and new Figure 5---figure supplement 1). Hence, LyNA1 and LyNa-VAs modulate TPCs via distinct mechanisms.

Second, based on the reviewers' suggestions, we explored the possible action site of LyNa-VAs by comparing the time course of activation in three different patch configurations: whole-cell (i.e., extracellular agonist application), inside-out (intracellular agonist application), and whole-endolysosome (intracellular agonist application). As channel activation in the whole-cell configuration was significantly slower, i.e., longer latency and time constant of activation, in comparison to cytosolic applications under the inside-out and whole-endolysosome configurations (see new Figure 1---figure supplement 2), the action site of LyNa-VAs is likely to be either intracellular or more accessible from the intracellular side.

Third, the reviewers asked us to examine the effects of multiple LyNa-VAs on TPC1 and various mutant TPC2 channels, including I551R, the presumed voltage-sensor mutation (She et al., 2018), and K204A, the PI(3,5)P~2~-binding-site mutation (She et al., 2019). We found that whereas both LyNa-VA1.1 and LyNa-VA1.2 activated TPC1, LyNa-VA2.1 instead inhibited TPC1 (new Figure 4D). Additionally, the I551R mutation, which converted TPC2 into a voltage-dependent outward-rectifying TPC1-like channel (She et al., 2018), failed to affect the voltage-dependent activation of inwardly-rectifying currents by LyNa-VAs (new Figure 4---figure supplement 2D-E). Furthermore, the lack of a synergistic effect between LyNa-VAs and PI(3,5)P~2~ on TPC2^K204A^ currents (new Figure 3C, 3D) suggested that Lys204 is the primary PI(3,5)P~2~-binding site. Collectively, the results obtained from these additional experiments have significantly strengthened the major conclusion of the paper: LyNa-VAs bind to activate TPCs via a voltage-dependent mechanism independent of PI(3,5)P~2~.

> Major comments:
>
> 1\) While the authors showed that the effect is specific to TPC channels the effect may not be direct and might be mediated by a signaling cascade. This could be determined by recording currents from excised patches in the absence and presence of the agonists. In addition, the comparison of the time-course of activation for inside-out and whole cell or outside-out patches may suggest if the agonist binding site is extracellular or intracellular.

Based on the reviewer's suggestion, we performed inside-out patch-clamp recordings in TPC2^LL/AA^-expressing HEK293 cells. Robust activation was seen in these cell-free excised patches (Figure 1---figure supplement 2), as well as in (cell-free) whole-endolysosome patches, suggesting that the effects of LyNa-VAs are most likely to be direct. As mentioned in the summary paragraphs (Experiment \#2), LyNa-VAs activated *I*~TPC2~ significantly faster (i.e., with shorter latency and smaller activation time-constant) in the inside-out and whole-endolysosome patches (Figure 1---figure supplement 2C and D) comparted with whole-cell recordings, suggesting that the agonist binding site is likely to be intracellular.

> 2\) For pharmacological comparisons it would be useful to determine the EC~50~ for TPC1 and at least a few of the identified agonists.

We have conducted the dose-dependent studies to show that whereas LyNa-VA1.1 and LyNa-VA1.2 activated whole-endolysosome*I*~TPC1~ with an EC~50~ of 27 ± 2 µM (n=3 patches) and 10 ± 1 µM (n=3), respectively, LyNa-VA2.1 inhibited *I*~TPC1~ (IC~50~ = 77 ± 2 µM, n=3; see Figure 4D). Also see Experiment \#3 in the summary paragraphs.

> 3\) Figure 3C could be strengthened by including dose-response data for K204 mutant. It is conceivable that the agonists might activate or expose additional PIP2 sites, distinct from the one destabilized by the K204A mutation. The dose-response experiments might reveal this possibility.

We agree with the reviewer and have examined the dose-dependent responses of TPC2^K204A^ in the presence and absence of PI(3,5)P~2~. Unlike wild-type (WT) channels, PI(3,5)P~2~ had little or no effect on the LyNa-VA dose-response of the TPC2^K204A^ channel (new Figure 3C and D), suggesting that Lys204 is essential for PI(3,5)P~2~ binding in TPC2 (She et al., 2019) in the presence and absence of LyNa-VAs.

> 4\) The effect of Riluzole is also very interesting and could be considered in more depth. The authors have not described the effect of Riluzole on TPC1 channels. Is it still voltage-independent? It is important to know if the mechanism of this agonist action is similar in the two channels, as it might help in identifying the molecular determinants of the effect. It also would be of interest to investigate the effect of Riluzole on TPC2 and R540I TPC1 mutant channels in the presence of PIP2. Both agonists show linear activation with voltage and therefore there is a possibility that they might be competitive.

Whereas TPC2 was activated by Riluzole (LyNA1) with an EC~50~ of 181 ± 6 µM (Figure 3---figure supplement 1E), TPC1 was, intriguingly, inhibited by Riluzole at the concentration of 150 µM (Figure 4---figure supplement 1C). Since the inhibition appeared to be voltage-independent (Figure 4---figure supplement 1C), we did not further study the Riluzole effect on TPC1^R540I^. On the other hand, although both PI(3,5)P~2~ and Riluzole are agonists of TPC2, PI(3,5)P~2~ did not further increase the potency of Riluzole (EC~50~ = 175 ± 19 µM) on *I*~TPC2~ (Figure 3---figure supplement 1E). Additionally, Riluzole activation was intact in TPC2^K204A^ channels (Figure 3---figure supplement 1B). Therefore, Riluzole and PI(3,5)P~2~ may activate TPC2 channels via distinct voltage-independent mechanisms.

> 5\) Since the hTPC2 currents activated by TCAs are so different (Figure 2C), the possibility exists that channels other than TPC2 mediate these currents. The authors should endeavor to show that an hTPC2-specific blocker also blocks TCA-activated currents.

We addressed the reviewer's concern on this by conducting several control experiments. First, we used a pharmacological approach to show that TCA-activated currents were inhibited by our unpublished, TPC-specific small-molecule inhibitor (LyNI-1; Lysosomal Na^+^ channel Inhibitor 1; see [Author response image 1](#respfig1){ref-type="fig"}). Note that Ned-19 and Tetrandine, two reported TPC blockers (Sakurai et al., 2015), are at best very weak inhibitors of *I*~TPC~ in our hands ([Author response image 1](#respfig1){ref-type="fig"}). Likewise, verapamil, a blocker that we reported previously, had very weak inhibitory effects on the inward currents of TPC2 (Wang et al., 2012). We will report the characterization work of LyNI-1 in a separate study focusing on the cell biological roles of TPC2. Second, we used a genetic approach to show that TCA-activated whole-endolysosome currents were present in WT, but not TPC1/2 DKO HAP1 cells (Figure 3E and F). Third, TCA-activated whole-cell currents were only detected in TPC2^LL/AA^-transfected, but not non-transfected HEK293 cells (Figure 1C and D). Fourth, TCA-activated currents had nearly identical P~K~/P~Na~ values compared with PI(3,5)P~2~-activated TPC2 currents (Figure 5), and the N653G mutation decreased the Na^+^-selectivity of both TCA- and PI(3,5)P~2~-activated TPC currents (Figure 5 andFigure 5---figure supplement 1). Taken together, these results suggest that TCA-induced currents are mediated by TPC2.

![LyNa-VA-induced currents are inhibited by LyNI-1, a small-molecule TPC2 inhibitor.\
(**A**) Dose-dependent inhibition of LyNI-1 on PI(3,5)P~2~ (0.1 µM)-induced whole-endolysosome *I*~TPC2~ (IC~50~ = 3 ± 1 µM, n=3 patches). (**B**) Co-application of LyNI-1(100 µM) inhibited LyNa-VA1.1 (50 µM)-evoked whole-endolysosome *I*~TPC2~.](elife-51423-resp-fig1){#respfig1}

> 6\) In the subsection "Cationic ion selectivity of TPC2 is not altered by LyNa-Vas", the authors make the argument that to probe if TCAs bind to the selectivity filter, they investigate possible changes in ion selectivity. They find that there are no changes in selectivity in the presence of TCAs and therefore these drugs do not bind at the selectivity filter. This argument is flawed; there is no reason to think that a drug binding in or near the selectivity filter necessarily alters the selectivity to ions.

We agree with the reviewer and have toned down the argument in the revision (see Discussion).

> 7\) Further, the authors mention a \"selectivity gate\" do they mean \"gate at the selectivity filter\"? If so, there is no evidence that TPC channel\'s gating occurs at the selectivity filter, like in CNG cation channels. It is sometimes wrongly assumed that all ions have gating at a bundle crossing (S6 gate) and at the selectivity filter.

We agree with the reviewer and have modified the discussion about the unverified "gate at the selectivity filter" of TPC channels (see Discussion).

> 8\) The last paragraph of the Discussion presents some discussion of the possible consequences of this newly described interaction between TCAs and lysosomal cation channels, however, there is no discussion of the possible mechanism of voltage-dependent gating induced in TPC channels and this is a major point of the manuscript.

We have expanded the discussion on the potential mechanisms that may contribute to TCA-induced voltage-dependent gating (see the first paragraph in Discussion).

> 9\) In Figure 1E, it is surprising that the magnitude of the currents is so similar between cells to have the size of errors presented. Surely there should be a large variability in the levels of expression. Please present all comparisons between currents as normalized current density (current/capacitance).

Based on the reviewer's suggestion, we have replaced the figure panel using normalized current density (new Figure 1E).

[^1]: These authors contributed equally to this work.
